- Home
- MYN vs PRTA Comparison
MYN vs PRTA Comparison
Compare MYN & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYN
- PRTA
- Stock Information
- Founded
- MYN 1992
- PRTA 2012
- Country
- MYN United States
- PRTA Ireland
- Employees
- MYN N/A
- PRTA N/A
- Industry
- MYN Finance Companies
- PRTA Biotechnology: Pharmaceutical Preparations
- Sector
- MYN Finance
- PRTA Health Care
- Exchange
- MYN Nasdaq
- PRTA Nasdaq
- Market Cap
- MYN 358.2M
- PRTA 366.6M
- IPO Year
- MYN N/A
- PRTA N/A
- Fundamental
- Price
- MYN $9.37
- PRTA $8.25
- Analyst Decision
- MYN
- PRTA Buy
- Analyst Count
- MYN 0
- PRTA 10
- Target Price
- MYN N/A
- PRTA $24.29
- AVG Volume (30 Days)
- MYN 86.0K
- PRTA 1.1M
- Earning Date
- MYN 01-01-0001
- PRTA 08-04-2025
- Dividend Yield
- MYN 4.12%
- PRTA N/A
- EPS Growth
- MYN N/A
- PRTA N/A
- EPS
- MYN N/A
- PRTA N/A
- Revenue
- MYN N/A
- PRTA $10,341,000.00
- Revenue This Year
- MYN N/A
- PRTA N/A
- Revenue Next Year
- MYN N/A
- PRTA $122.46
- P/E Ratio
- MYN N/A
- PRTA N/A
- Revenue Growth
- MYN N/A
- PRTA N/A
- 52 Week Low
- MYN $8.47
- PRTA $4.32
- 52 Week High
- MYN $10.62
- PRTA $22.83
- Technical
- Relative Strength Index (RSI)
- MYN 50.46
- PRTA 75.08
- Support Level
- MYN $9.12
- PRTA $7.39
- Resistance Level
- MYN $9.47
- PRTA $8.17
- Average True Range (ATR)
- MYN 0.08
- PRTA 0.45
- MACD
- MYN 0.02
- PRTA 0.09
- Stochastic Oscillator
- MYN 69.44
- PRTA 95.07
About MYN Blackrock MuniYield New York Quality Fund Inc.Common Stock
Blackrock Muniyield NY Quality FD, Inc is a closed-end management investment company. Its objective is to provide shareholders with a high level of current income exempt from federal income taxes. The Fund invests in long-term municipal obligations that are investment grade quality or are considered by the Fund's investment adviser to be of comparable quality, at the time of investment.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.